These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 30052449)
1. Changes in Physical Stability of Supercooled Etoricoxib after Compression. Rams-Baron M; Pacułt J; Jędrzejowska A; Knapik-Kowalczuk J; Paluch M Mol Pharm; 2018 Sep; 15(9):3969-3978. PubMed ID: 30052449 [TBL] [Abstract][Full Text] [Related]
2. Molecular Factors Governing the Liquid and Glassy States Recrystallization of Celecoxib in Binary Mixtures with Excipients of Different Molecular Weights. Grzybowska K; Chmiel K; Knapik-Kowalczuk J; Grzybowski A; Jurkiewicz K; Paluch M Mol Pharm; 2017 Apr; 14(4):1154-1168. PubMed ID: 28241116 [TBL] [Abstract][Full Text] [Related]
3. Study of Thermal Properties, Molecular Dynamics, and Physical Stability of Etoricoxib Mixtures with Octaacetylmaltose near the Glass Transition. Grzybowska K; Rams-Baron M; Łucak K; Grzybowski A; Paluch M Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077212 [TBL] [Abstract][Full Text] [Related]
4. Effect of Polymer Chain Length on the Physical Stability of Amorphous Drug-Polymer Blends at Ambient Pressure. Pacułt J; Rams-Baron M; Chrząszcz B; Jachowicz R; Paluch M Mol Pharm; 2018 Jul; 15(7):2807-2815. PubMed ID: 29791165 [TBL] [Abstract][Full Text] [Related]
5. Toward a Better Understanding of the Physical Stability of Amorphous Anti-Inflammatory Agents: The Roles of Molecular Mobility and Molecular Interaction Patterns. Rams-Baron M; Wojnarowska Z; Grzybowska K; Dulski M; Knapik J; Jurkiewicz K; Smolka W; Sawicki W; Ratuszna A; Paluch M Mol Pharm; 2015 Oct; 12(10):3628-38. PubMed ID: 26323061 [TBL] [Abstract][Full Text] [Related]
6. Co-Stabilization of Amorphous Pharmaceuticals-The Case of Nifedipine and Nimodipine. Knapik-Kowalczuk J; Tu W; Chmiel K; Rams-Baron M; Paluch M Mol Pharm; 2018 Jun; 15(6):2455-2465. PubMed ID: 29738666 [TBL] [Abstract][Full Text] [Related]
7. Solubility advantage from amorphous etoricoxib solid dispersions. Dani P; Puri V; Bansal AK Drug Dev Ind Pharm; 2014 Jan; 40(1):92-101. PubMed ID: 23301771 [TBL] [Abstract][Full Text] [Related]
8. The role of polymer concentration on the molecular mobility and physical stability of nifedipine solid dispersions. Kothari K; Ragoonanan V; Suryanarayanan R Mol Pharm; 2015 May; 12(5):1477-84. PubMed ID: 25894099 [TBL] [Abstract][Full Text] [Related]
9. Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers. Dhumal RS; Shimpi SL; Paradkar AR Acta Pharm; 2007 Sep; 57(3):287-300. PubMed ID: 17878109 [TBL] [Abstract][Full Text] [Related]
10. Investigation on Formulation Strategies to Mitigate Compression-Induced Destabilization in Supersaturated Celecoxib Amorphous Solid Dispersions. Be Rziņš KR; Fraser-Miller SJ; Walker GF; Rades T; Gordon KC Mol Pharm; 2021 Oct; 18(10):3882-3893. PubMed ID: 34529437 [TBL] [Abstract][Full Text] [Related]
11. Molecular Dynamics, Recrystallization Behavior, and Water Solubility of the Amorphous Anticancer Agent Bicalutamide and Its Polyvinylpyrrolidone Mixtures. Szczurek J; Rams-Baron M; Knapik-Kowalczuk J; Antosik A; Szafraniec J; Jamróz W; Dulski M; Jachowicz R; Paluch M Mol Pharm; 2017 Apr; 14(4):1071-1081. PubMed ID: 28231007 [TBL] [Abstract][Full Text] [Related]
12. Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture. Rumondor AC; Marsac PJ; Stanford LA; Taylor LS Mol Pharm; 2009; 6(5):1492-505. PubMed ID: 19634917 [TBL] [Abstract][Full Text] [Related]
13. Molecular mobility-based estimation of the crystallization rates of amorphous nifedipine and phenobarbital in poly(vinylpyrrolidone) solid dispersions. Aso Y; Yoshioka S; Kojima S J Pharm Sci; 2004 Feb; 93(2):384-91. PubMed ID: 14705195 [TBL] [Abstract][Full Text] [Related]
14. Prediction of onset of crystallization in amorphous pharmaceutical systems: phenobarbital, nifedipine/PVP, and phenobarbital/PVP. Caron V; Bhugra C; Pikal MJ J Pharm Sci; 2010 Sep; 99(9):3887-900. PubMed ID: 20575050 [TBL] [Abstract][Full Text] [Related]
15. Relaxation Dynamics vs Crystallization Kinetics in the Amorphous State: The Case of Stiripentol. Ruiz GN; Romanini M; Barrio M; Tamarit JL; Pardo LC; Macovez R Mol Pharm; 2017 Nov; 14(11):3636-3643. PubMed ID: 28915351 [TBL] [Abstract][Full Text] [Related]
16. Mechanism-based selection of stabilization strategy for amorphous formulations: Insights into crystallization pathways. Edueng K; Mahlin D; Larsson P; Bergström CAS J Control Release; 2017 Jun; 256():193-202. PubMed ID: 28412224 [TBL] [Abstract][Full Text] [Related]
17. How can we improve the physical stability of co-amorphous system containing flutamide and bicalutamide? The case of ternary amorphous solid dispersions. Pacult J; Rams-Baron M; Chmiel K; Jurkiewicz K; Antosik A; Szafraniec J; Kurek M; Jachowicz R; Paluch M Eur J Pharm Sci; 2019 Aug; 136():104947. PubMed ID: 31170526 [TBL] [Abstract][Full Text] [Related]
18. Kinetic stability of amorphous solid dispersions with high content of the drug: A fast scanning calorimetry investigation. Lapuk SE; Zubaidullina LS; Ziganshin MA; Mukhametzyanov TA; Schick C; Gerasimov AV Int J Pharm; 2019 May; 562():113-123. PubMed ID: 30902705 [TBL] [Abstract][Full Text] [Related]
19. Comparative Physical Study of Three Pharmaceutically Active Benzodiazepine Derivatives: Crystalline versus Amorphous State and Crystallization Tendency. Valenti S; Barrio M; Negrier P; Romanini M; Macovez R; Tamarit JL Mol Pharm; 2021 Apr; 18(4):1819-1832. PubMed ID: 33689364 [TBL] [Abstract][Full Text] [Related]
20. Study on mechanism for amorphous drug stabilization using gelucire 50/13. Shimpi SL; Mahadik KR; Paradkar AR Chem Pharm Bull (Tokyo); 2009 Sep; 57(9):937-42. PubMed ID: 19721253 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]